141 related articles for article (PubMed ID: 23335699)
1. [Aberrant immunophenotypes in acute leukemia in a Buenos Aires' hospital population].
Novoa V; Núñez NA; Carballo OG; Lessa CF
Medicina (B Aires); 2013; 73(1):9-16. PubMed ID: 23335699
[TBL] [Abstract][Full Text] [Related]
2. Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia.
Babusíková O; Glasová M; Koníková E; Kusenda J
Neoplasma; 1996; 43(6):367-72. PubMed ID: 8996560
[TBL] [Abstract][Full Text] [Related]
3. Leukemic cells and aberrant phenotypes in acute leukemia patients: a flow cytometry analysis.
Vosková D; Váleková L; Fedorová J; Hudecek J; Kubisz P
Neoplasma; 2003; 50(6):422-7. PubMed ID: 14689063
[TBL] [Abstract][Full Text] [Related]
4. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis.
Rothe G; Schmitz G
Leukemia; 1996 May; 10(5):877-95. PubMed ID: 8656686
[TBL] [Abstract][Full Text] [Related]
5. Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance.
Bahia DM; Yamamoto M; Chauffaille Mde L; Kimura EY; Bordin JO; Filgueiras MA; Kerbauy J
Haematologica; 2001 Aug; 86(8):801-6. PubMed ID: 11522535
[TBL] [Abstract][Full Text] [Related]
6. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.
Zelezníková T; Babusíková O
Neoplasma; 2005; 52(6):517-22. PubMed ID: 16284699
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
Li X; Du W; Liu W; Li X; Li H; Huang SA
APMIS; 2010 May; 118(5):353-9. PubMed ID: 20477810
[TBL] [Abstract][Full Text] [Related]
8. Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report.
Naghashpour M; Lancet J; Moscinski L; Zhang L
Am J Hematol; 2010 Jun; 85(6):451-4. PubMed ID: 20513125
[TBL] [Abstract][Full Text] [Related]
9. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
10. [Immunophenotyping of 222 children with acute leukemia by multi-color flow cytometry].
Shen HQ; Tang YM; Yang SL; Qian BQ; Song H; Shi SW; Xu WQ
Zhonghua Er Ke Za Zhi; 2003 May; 41(5):334-7. PubMed ID: 14751050
[TBL] [Abstract][Full Text] [Related]
11. [Cellular immunophenotypes in 97 adults with acute leukemia].
Piedras J; López-Karpovitch X; Cárdenas MR
Rev Invest Clin; 1997; 49(6):457-64. PubMed ID: 9528305
[TBL] [Abstract][Full Text] [Related]
12. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
13. Expression of aberrant CD markers in acute leukemia: a study of 100 cases with immunophenotyping by multiparameter flowcytometry.
Sarma A; Hazarika M; Das D; Kumar Rai A; Sharma JD; Bhuyan C; Kataki AC
Cancer Biomark; 2015; 15(4):501-5. PubMed ID: 25835176
[TBL] [Abstract][Full Text] [Related]
14. [Immunophenotyping of acute lymphatic leukemia: diagnostic aspects and clinical relevance].
Ludwig WD; Reiter A; Schott G; Schwartz S; Thiel E
Wien Klin Wochenschr; 1994; 106(8):231-2, 233-7. PubMed ID: 8023515
[TBL] [Abstract][Full Text] [Related]
15. [Immunophenotyping of acute leukemias: diagnostic and pronostic utility in Abidjan, Côte d'Ivoire].
Inwoley KA; Sawadogo D; Mizero L; Salou M; Karim N; Sangaré A
Bull Soc Pathol Exot; 2004; 97(5):319-22. PubMed ID: 15787262
[TBL] [Abstract][Full Text] [Related]
16. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination.
Thalhammer-Scherrer R; Mitterbauer G; Simonitsch I; Jaeger U; Lechner K; Schneider B; Fonatsch C; Schwarzinger I
Am J Clin Pathol; 2002 Mar; 117(3):380-9. PubMed ID: 11888077
[TBL] [Abstract][Full Text] [Related]
17. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric analysis of Mixed phenotype acute leukemia: experience from a tertiary oncology center.
Sukumaran R; Nair RA; Jacob PM; Nair Anila KA; Prem S; Binitha R; Kusumakumary P
Indian J Pathol Microbiol; 2015; 58(2):181-6. PubMed ID: 25885130
[TBL] [Abstract][Full Text] [Related]
19. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping.
Wuchter C; Ratei R; Spahn G; Schoch C; Harbott J; Schnittger S; Haferlach T; Creutzig U; Sperling C; Karawajew L; Ludwig WD
Haematologica; 2001 Feb; 86(2):154-61. PubMed ID: 11224484
[TBL] [Abstract][Full Text] [Related]
20. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
Al-Mawali A; Gillis D; Hissaria P; Lewis I
Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
